Search
XMT-1001
go.drugbank.com/drugs/DB06069InvestigationalIn this novel CPT pro-drug, CPT is conjugated with a 70 kDa biodegradable hydrophilic polyacetal, poly (1-hydroxymethylene hydroxylmethylformal). … XMT-1001 has demonstrated an improved therapeutic window as compared with CPT and irinotecan in human tumor xenografts models
Categories: Compounds used in a research, industrial, or household settingElbasvir
go.drugbank.com/drugs/DB11574ApprovedElbasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly. … [A19626] In a computational target-based drug repurposing investigation published in April 2020, elbasvir was predicted to bind stably and preferentially to three proteins necessary for viral replication
Lycopene
go.drugbank.com/drugs/DB11231ApprovedHowever, lycopene is a potent antioxidant molecule that scavenges reactive oxygen species (ROS) singlet oxygen. Tomato lycopene extract is used as a color additive in food products. … Lycopene is a naturally occurring red carotenoid pigment that is responsible for red to pink colors seen in tomatoes, pink grapefruit, and other foods [A27242].
Categories: Compounds used in a research, industrial, or household settingModified vaccinia ankara
go.drugbank.com/drugs/DB15483ApprovedInvestigationalModified Vaccinia Ankara (MVA) refers to an attenuated strain of the Vaccinia virus. … Vaccines using MVA are live and non-replicating, and are produced using Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN).[L42660,L42670]
Synonyms: MVA-BNBosutinib
go.drugbank.com/drugs/DB06616ApprovedInvestigationalPhiladelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein. … [A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexGlycerol phenylbutyrate
go.drugbank.com/drugs/DB08909ApprovedInvestigationalGlycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Oxycodegol
go.drugbank.com/drugs/DB14146InvestigationalThe lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique characteristic compared to others in the opioid class [A33997, A34016]. … Nektar Therapeutics has filed an application for FDA approval of Loxicodegol for use in the treatment of chronic lower back pain [L3263]
Conivaptan
go.drugbank.com/drugs/DB00872ApprovedIt was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). … Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin).
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: Vaprisol Dextrose In Plastic ContainerBisoctrizole
go.drugbank.com/drugs/DB11262ApprovedBisoctrizole is not approved by the FDA, but is approved in the EU and other parts of the world as a UV-filter in sunscreens, day care products and skin lightening products at a maximum concentration of … It is a benzotriazole-based organic compound that absorbs, reflects, and scatters both UV-A and UV-B rays.
Nogapendekin alfa
go.drugbank.com/drugs/DB18740ApprovedInvestigationalIt is one of the active ingredients in Anktiva, a combination product also containing [inbakicept], where a single inbakicept is complexed with two nogapendekin alfa components. … [L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without